Clinical Trial: A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07161687) titled 'A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.' on Sept. 02.

Brief Summary: A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.

Study Start Date: Sept. 30

Study Type: OBSERVATIONAL

Condition: Hemophilia A or B

Intervention: DRUG: Marstacimab

For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcutaneously at a dose of 300 mg as the initial dose, followed by 150 mg once weekly. If the patient weighs 50 kg or more and shows an inadequate re...